הפירמה חושבת שלמרות שמחיר המניה של Align עלה מתחילת השנה, היא עדיין מציעה אחת ההזדמנויות הטובות ביותר לרווח בהשוואה לחברות אחרות שהם עוקבים אחריהן, לפי האנליסט.
הפירמה חושבת שלמרות שמחיר המניה של Align עלה מתחילת השנה, היא עדיין מציעה אחת ההזדמנויות הטובות ביותר לרווח בהשוואה לחברות אחרות שהם עוקבים אחריהן, לפי האנליסט.
Stifel raised the firm’s price target on Align Technology to $350 from $340 and keeps a Buy rating on the shares. Despite Align’s year-to-date move up, the firm believe Align
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), Align Tech (ALGN – Research Report) and Jazz Pharmaceuticals (JAZZ – Research Report) with bullish sentiments.
Intuitive Surgical (ISRG)
In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Intuitive Surgical, with a price target of $420.00. The company’s shares closed last Thursday at $384.31, close to its 52-week high of $403.00.
According to TipRanks.com, Wise is a 4-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $415.82, implying an 8.5% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $425.00 price target.
See today’s best-performing stocks on TipRanks >>
Align Tech (ALGN)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Align Tech, with a price target of $350.00. The company’s shares closed last Thursday at $316.92.
According to TipRanks.com, Block is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $301.44 average price target, implying a -6.5% downside from current levels. In a report issued on March 13, Piper Sandler also reiterated a Buy rating on the stock with a $355.00 price target.
Jazz Pharmaceuticals (JAZZ)
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $230.00. The company’s shares closed last Thursday at $118.30.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $185.34, representing a 57.7% upside. In a report issued on February 29, Needham also maintained a Buy rating on the stock with a $220.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ISRG:
Notable gainers among liquid option names this morning include Freeport McMoRan (FCX) $42.47 +2.11, NextEra Energy (NEE) $59.87 +2.72, Valero (VLO) $157.81 +7.08, FMC Corporation (FMC) $66.70 +2.85, and Align
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Align Tech (ALGN – Research Report), Legend Biotech (LEGN – Research Report) and Aslan Pharmaceuticals (ASLN – Research Report) with bullish sentiments.
Align Tech (ALGN)
Piper Sandler analyst Jason Bednar reiterated a Buy rating on Align Tech today and set a price target of $355.00. The company’s shares closed last Tuesday at $310.68.
According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $300.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Legend Biotech (LEGN)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech, with a price target of $87.00. The company’s shares closed last Tuesday at $65.13.
According to TipRanks.com, Kapoor has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $87.36, which is a 34.9% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $80.00 price target.
Aslan Pharmaceuticals (ASLN)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Aslan Pharmaceuticals, with a price target of $10.00. The company’s shares closed last Tuesday at $0.69, close to its 52-week low of $0.39.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals with a $10.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALGN: